CME three-lens brief
Evidence-based stock research on CME. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
50-day MA below 200-day MA (death-cross regime); price below both. · Underperforming SPY by 15.3pp over 30 days.
- 50-day MA below 200-day MA (death-cross regime); price below both.
- Underperforming SPY by 15.3pp over 30 days.
- Analyst mean target $288.73 — 22% above current (15 analysts).
- Earnings scheduled 2026-07-22.
CME closed at $237.51 (-0.92%) as of 2026-07-10. Market cap: $85.82B. P/E (trailing) 20.3. Price is below the 50-day MA and below the 200-day MA. Positives: analyst mean target $288.73 — 22% above current (15 analysts).. Concerns: 50-day MA below 200-day MA (death-cross regime); price below both.; underperforming SPY by 15.3pp over 30 days.. Last quarter: Revenue $1.88B, net income $0.00, free cash flow $3.03B. Watching for: 2026-07-22 earnings release (11 days out).
Why three lenses on CME, not one.
A single reasoning model has blind spots it doesn’t know about. We examine CMEacross Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/CME" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath CME brief"></iframe>